Brightsurf Science News & Current Events

May 31, 2014
Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease
A study presented at the American Society of Clinical Oncology Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).

Clinical trial shows drug combination may be highly effective in recurrent ovarian cancer
Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology meeting in Chicago today.

ASCO: One step closer to a breath test for lung cancer
Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease, but can also define the stage of any cancer present.

Studies reveal new strategies to improve quality of life
Key studies released today at the 50th Annual Meeting of the American Society of Clinical Oncology identify new strategies for easing the short- and long-term effects of cancer therapy and improving the quality of life of patients with cancer, as well as their caregivers.

Studies reveal potential new targeted therapies for common, hard-to-treat cancers
Positive results from four clinical trials of investigational targeted drugs for advanced ovarian, lung, and thyroid cancers, and chronic lymphocytic leukemia were highlighted today at the 50th Annual Meeting of the American Society of Clinical Oncology.

Immune therapy for advanced bladder cancer yields promising results
A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report.

Clinical trial shows drug combination may be effective in recurrent ovarian cancer
Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology meeting in Chicago today.

Risk of death highest following surgery in afternoons, at weekends, and in February
New research presented at this year's Euroanaesthesia show that on weekends, in the afternoons and in February are the times when the risk of death following surgery is the highest.

Phase 3 study strengthens support of ibrutinib as second-line therapy for CLL
In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia, ibrutinib significantly outperformed ofatumumab as a second-line therapy, according to a multicenter interim study published in the OnLine First edition of the New England Journal of Medicine.

The ethics of knowing where to stop treatment in a sick and elderly patient
An Emeritus Professor of medical ethics at Imperial College London will deliver a presentation at this year's Euroanaesthesia meeting titled 'Escalating care for the co-morbid elderly -- where do we stop?'

ALK, ROS1 and now NTRK1: Study shows prevalence of new genetic driver in lung cancer
ASCO study reports the prevalence of the NTRK1 mutation in an unselected population of 450 lung cancer samples, with >1 percent of patients testing positive.

Poor coverage of specific gene sets in exome sequencing gives cause for concern
Researchers have analysed 44 exome datasets from four different testing kits and shown that they missed a high proportion of clinically relevant regions.

Mount Sinai researchers to present studies at American Society of Clinical Oncology Meeting
Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2014 American Society of Clinical Oncology meeting May 30-June 3, 2014, in Chicago, including data on new treatment approaches for thyroid, head and neck, and recurrent ovarian cancers; and new biomarkers for bile duct cancers.

Results in Phase I trial of OMP-54F28, a Wnt inhibitor targeting cancer stem cells
At the 50th Annual Meeting of the American Society for Clinical Oncology, University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28, an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells.

Patients with metastatic colon cancer respond to new combination therapy
In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan.

New Population Council research presented at 13th ESC Annual Congress
This week, the Population Council presented new research at the 13th Congress of the European Society of Contraception and Reproductive Health.

Study of 55 million people adds further evidence that patients admitted to hospital at weekends have higher mortality
A systematic review and meta-analysis of hospital data worldwide, presented as this year's Euroanaesthesia meeting in Stockholm, adds further evidence that patients admitted to hospital at weekends have higher mortality than those admitted on weekdays.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.